People

CEPA’s Strategy Review of The Global Fund to Fight AIDS, Tuberculosis and Malaria is published

CEPA was appointed to conduct the end-term strategic review of The Global Fund for 2017-22.

CEPA supports water, regulatory finance and global health practices with promotions to its partnership

Join us in congratulating Tom Cochrane and Kaveri Kumar on their recent promotions to the firm’s partnership. They join CEPA’s existing global Partners to lead a growing team of more than 50 economic, public and financial policy consulting experts.

CEPA evaluates Unitaid’s $22m investment aimed at supporting access to medicines

Our Global Health team's evaluation of Unitaid's portfolio to 'support access to medicines through innovative use of Trade Related Aspects of Intellectual Property Rights' has been published.

Our report on “Accelerating the Equitable Deployment and Access to Innovations” is published by the Global Fund

A technical evaluation by CEPA's Global Health team, to assess how the Global Fund is performing in terms of supporting innovations.

CEPA’s independent outcome evaluation of CEPI is published

Dr Richard Hatchett, the Chief Executive Officer of The Coalition for Epidemic Preparedness Innovations praises our work, describing it as “a fair, balanced and independent perspective”.

Operational review of Global Fund supported HIV prevention programs for Adolescent Girls and Young Women

CEPA was commissioned by the Global Fund to fight AIDS, Tuberculosis and Malaria (the Global Fund) to conduct an operational review of Global Fund-supported HIV prevention programs for AGYW across 13 priority countries in sub-Saharan Africa.

Independent Outcome Evaluation for The Coalition for Epidemic Preparedness Innovations

Our global health team's Independent Outcome Evaluation has been published by The Coalition for Epidemic Preparedness Innovations (CEPI).

The potential impact of future innovation in support of Unitaid’s strategy

We explored the potential impact of ten promising innovations that Unitaid may support during its 2023-27 strategic period, which could make a significant contribution to advancing global health targets.

Evaluation of Unitaid’s COVID-19 portfolio of investments

CEPA was appointed by Unitaid to undertake a portfolio-level evaluation assessing the contribution of Unitaid’s COVID-19 response and alignment with the ACT-A partnership.

Evaluation of the UNAIDS contribution to Efficient and Sustainable Financing

CEPA was appointed by the UNAIDS Independent Evaluation Office to lead an evaluation of the Joint Programme’s work on equitable, efficient and sustainable financing for the HIV response.

Unitaid HIV self-testing evaluation

End of project evaluation of Unitaid’s HIV Self-testing (HIVST) portfolio.

CEPA modelling shows the economic and public health impact of voluntary licensing

Licences negotiated by the Medicines Patent Pool will save the international community an estimated USD 3.5bn and 170k lives by 2030. This is according to a new methodology for estimating the impact of licences that was validated via a peer-reviewed article published in The Lancet.

CEPA evaluates Unitaid’s investments in Hepatitis C

Unitaid has invested more than US$45 million since 2015 in support of improving access to care for hepatitis C. We are pleased to have provided them with a portfolio evaluation and end of grant evaluations.

Unitaid molecular diagnostics portfolio review

CEPA was appointed by Unitaid to conduct a portfolio-level joint end-of-grant evaluation of its investments in Point of Care (POC) molecular diagnostics for HIV.

Evaluation of the Partnership for Maternal, Newborn and Child Health (PMNCH)

CEPA was commissioned by the PMNCH Board to conduct an external evaluation of PMNCH. The evaluation was of strategic importance in the context of developing the next Strategic Plan for PMNCH for the period 2021-2025.

Gavi supply and procurement strategy evaluation

CEPA was appointed by Gavi to conduct an evaluation of the 2016-20 Supply and Procurement Strategy (their market shaping strategy). This large-scale evaluation involved an assessment of the design, implementation and results of the strategy.

TERG / Global Fund HIV primary prevention review

The Global Fund Technical Evaluation Reference Group (TERG) commissioned CEPA to conduct a review of the Global Fund’s investments in HIV primary prevention.

Power of Nutrition Results Framework

CEPA was engaged to evaluate CEPI's results management system. This focused on assessing whether the approach to monitoring and reporting results was relevant, meeting the needs of its donors.

Evaluation of cooperation agreements between health organisations

The Global Fund commissioned CEPA to conduct an evaluation of its Cooperation Agreements with WHO and the Stop TB Partnership on the provision of technical assistance to support the development of country concept notes and grant-making.

Thematic review to assess an approach to investing in resilient & sustainable systems for health

CEPA conducted a thematic review to assess the Global Fund’s current approach to investments in Resilient and Sustainable Systems for Health (RSSH).

Evaluation of community, human rights and gender interventions

CEPA was appointed to develop an evaluation framework and methodology to help the Stop TB Partnership to evaluate its community, human rights and gender focused work.

Evaluation of Gavi health system strengthening support to Nepal

Gavi commissioned an evaluation of its Health System Strengthening (HSS) support to Nepal through the pooled funding mechanism.

Mid-term evaluation of the Unitaid “Self-testing Africa (STAR)” project

CEPA was appointed to review the implementation of the first phase of Unitaid’s HIV self-testing grant to identify areas that worked well and those that worked less well, determine the extent to which the project achieved its intended impacts.

Evaluation of Gavi Phase II

A consortium led by CEPA carried out the second evaluation of Gavi. The evaluation assessed Gavi’s performance since inception, focusing on the period between 2006 and 2009.